Biotech RadarJobs updated

COMPANY

PTC Therapeutics

HQ: Warren, NJ source · ptcbio.com ↗ · Mid-Atlantic

FDA-approved therapeutic company Clinical Phase 3

43 open jobs · last seen Oct 23, 2026 · 53 sources

Profile checked Oct 10, 2026

Keywords: Duchenne Muscular Dystrophy Phenylketonuria Friedreich Ataxia Leigh Syndrome Muscular Dystrophies Atrophic Muscular Disorders Muscular Diseases Neuromuscular Diseases Nervous System Diseases X-Linked Genetic Diseases Inborn Genetic Diseases Becker Muscular Dystrophy Cystic Fibrosis Friedreich's Ataxia Mitochondrial Diseases Amyotrophic Lateral Sclerosis Leiomyosarcoma Aniridia Musculoskeletal Diseases Rheumatoid Arthritis AADC Deficiency Drug Resistant Epilepsy Leigh Disease Mitochondrial Encephalopathy (MELAS) Pontocerebellar Hypoplasia Type 6 (PCH6) Alpers Disease Alpers Syndrome Musculoskeletal Disease Inherited Mitochondrial Disease Nonsene Mutation Duchenne Muscular Dystrophy BH4 Deficiency Hyperphenylalaninemia Pneumonia COVID-19 Coronavirus Limb-Girdle Muscular Dystrophy Leukemia, Myeloid, Acute AML Gastroparesis Dystrophinopathy

43Open jobs65Trials (company is sponsor)2FDA records (2 yrs)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Manager, Statistical Programming3 locations, including Warren, New Jersey, USAOct 22, 2026Oct 9, 2026
Senior Manager, Global Clinical Regulatory LeadUSA - New Jersey - WarrenOct 22, 2026Oct 9, 2026
Marketing & Communications ManagerTokyoOct 22, 2026Oct 21, 2026
Associate Director, Clinical Operations8 locations, including Warren, New Jersey, USAOct 21, 2026Oct 9, 2026
Senior Manager, Clinical Operations8 locations, including Warren, New Jersey, USAOct 21, 2026Oct 9, 2026

See all 43 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (43 open jobs at last check). source ↗
  2. Trial start Phase 2: Study of PTC844 in Participants With Active Rheumatoid Arthritis source ↗
  3. Trial start Phase 3: Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA) source ↗
  4. FDA FDA New drug/biologic (novel): SEPHIENCE (sepiapterin) — NDA219666, Jul 28, 2025. Applicant at approval: PTC Therapeutics, Inc. source ↗
  5. Partnership Partnership / licensing: $1B (upfront, as published); deal value up to $1.9B (kept separate from upfront), announced Dec 2, 2024. Source: SEC filing. source ↗
  6. FDA FDA New drug/biologic (novel): KEBILIDI (eladocagene exuparvovec-tneq) — BLA125722, Nov 13, 2024. Applicant at approval: PTC Therapeutics, Inc. source ↗
  7. Trial start Phase 3: A Study of Sepiapterin in Participants With Phenylketonuria (PKU) source ↗
  8. Trial start Phase 3: A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia source ↗
  9. Trial start Phase 2: A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia source ↗
  10. Trial start Phase 3: A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease source ↗
  11. Trial start Phase 2/Phase 3: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) source ↗
  12. Trial start Phase 2: Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS source ↗
  13. Trial start Phase 3: A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria source ↗
  14. Trial start Phase 2: A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) source ↗
  15. Trial start Phase 3: A Study of PTC923 in Participants With Phenylketonuria source ↗
  16. Trial start Phase 2: A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants source ↗
  17. Trial start Phase 2/Phase 3: A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia source ↗
  18. Trial start Phase 2/Phase 3: A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy source ↗
  19. Trial start Phase 2/Phase 3: A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) source ↗
  20. Trial start Phase 3: A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I) source ↗
  21. Trial start Phase 2: A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren source ↗
  22. Trial start Phase 1: A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) source ↗
  23. Trial start Phase 2: A Study of CNSA-001 in Women With Diabetic Gastroparesis source ↗
  24. Trial start Phase 1/Phase 2: A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia source ↗
  25. Trial start 2: A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia source ↗

Showing 25 of 53 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 43

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Manager, Statistical Programming3 locations, including Warren, New Jersey, USAOct 22, 2026Oct 9, 2026Senior
Senior Manager, Global Clinical Regulatory LeadUSA - New Jersey - WarrenOct 22, 2026Oct 9, 2026Senior
Marketing & Communications ManagerTokyoOct 22, 2026Oct 21, 2026Not stated
Associate Director, Clinical Operations8 locations, including Warren, New Jersey, USAOct 21, 2026Oct 9, 2026Senior
Senior Manager, Clinical Operations8 locations, including Warren, New Jersey, USAOct 21, 2026Oct 9, 2026Senior
Senior Manager, Clinical Operations8 locations, including Warren, New Jersey, USAOct 20, 2026Oct 9, 2026Not stated
Patient Support Specialist - Bilingual (West Coast Candidates)3 locations (listed on the posting)Oct 20, 2026Oct 21, 2026Not stated
Key Account Manager JapanJapan (Remote)Oct 20, 2026Oct 21, 2026Not stated
Contractor, Clinical OperationsUSA - New Jersey - WarrenOct 19, 2026Oct 9, 2026Not stated
Senior Manager, BiostatisticsUSA - New Jersey - WarrenOct 19, 2026Oct 20, 2026Not stated
Senior Manager, Manufacturing Science and Technology - Drug ProductIreland - DublinOct 16, 2026Oct 16, 2026Not stated
Associate Director, EU Data Protection Officer (DPO)2 locations, including Dublin, IrelandOct 14, 2026Oct 15, 2026Senior
Key Account Manager, Italy CentralItaly (Remote)Oct 14, 2026Oct 15, 2026Mid
Key Account Manager, Italy South.Italy (Remote)Oct 14, 2026Oct 15, 2026Mid
MSL I - Doenças Raras (Nordeste, Centro-oeste ou São Paulo)2 locations (listed on the posting)Oct 13, 2026Oct 14, 2026Mid
Senior Director, BiostatisticsUSA - New Jersey - WarrenOct 12, 2026Oct 14, 2026Senior
Director, Global Compensation and EquityUSA - New Jersey - WarrenOct 9, 2026Oct 9, 2026Senior
Manager, Total RewardsIreland - DublinOct 9, 2026Oct 9, 2026Senior
Contractor, Drug Metabolism and Pharmacokinetics (DMPK)USA - New Jersey - BridgewaterOct 8, 2026Oct 9, 2026Mid
Associate Director, Pharmacovigilance - Safety Scientist3 locations, including Guildford, United KingdomOct 8, 2026Oct 9, 2026Senior
Contractor, Accounting AnalystBrazil - Sao PauloOct 7, 2026Oct 9, 2026Mid
Regional Account Manager-Eastern Midwest RegionRemote (United States)Oct 7, 2026Oct 9, 2026Mid
Regional Account Manager -Northeast/Eastern RegionNot listedOct 7, 2026Oct 9, 2026Mid
Contractor, GxP Bioanalytical Scientist, Clinical PharmacologyUSA - New Jersey - PenningtonOct 6, 2026Oct 9, 2026Entry
Senior Director, Clinical Development9 locations, including Warren, New Jersey, USAOct 5, 2026Oct 9, 2026Senior
Director, Clinical Development9 locations, including Warren, New Jersey, USAOct 5, 2026Oct 9, 2026Senior
Contractor, Clinical Data ManagementUSA - New Jersey - WarrenOct 1, 2026Oct 9, 2026Senior
Associate Director, Manufacturing Science and Technology – Drug ProductUSA - New Jersey - WarrenSep 30, 2026Oct 9, 2026Senior
Regional Account Manager - Upstate NYRemote(US-New York)Sep 30, 2026Oct 9, 2026Mid
Director, Project ManagementUSA - New Jersey - WarrenSep 29, 2026Oct 9, 2026Senior
Senior Manager, Clinical Data ManagementUSA - New Jersey - WarrenSep 29, 2026Oct 9, 2026Senior
Medical Science Liaison - Metabolic (Mid Atlantic)7 locations (listed on the posting)Sep 28, 2026Oct 9, 2026Entry
Contractor, Global Medical Affairs OperationsUSA - New Jersey - WarrenSep 24, 2026Oct 9, 2026Mid
Patient Engagement Liaison (Midwest)4 locations (listed on the posting)Sep 24, 2026Oct 9, 2026Mid
Patient Engagement Liaison (Mid-Atlantic/Ohio Valley)4 locations (listed on the posting)Sep 24, 2026Oct 9, 2026Mid
Associate Director, Clinical SuppliesUSA - New Jersey - WarrenSep 23, 2026Oct 9, 2026Senior
Medical Value DirectorRemote (United States)Sep 23, 2026Oct 9, 2026Senior
Senior Scientist, Analytical DevelopmentUSA - New Jersey - BridgewaterSep 23, 2026Oct 9, 2026Senior
Medical Science LiaisonFrance - ParisSep 23, 2026Oct 9, 2026Senior
Associate Director, Regulatory Affairs - CMCNot listedSep 23, 2026Oct 9, 2026Senior
Associate Manager, Financial Planning & Analysis -Commercial FunctionsUSA - New Jersey - WarrenSep 23, 2026Oct 9, 2026Mid
Director, Clinical Data ManagementUSA - New Jersey - WarrenSep 23, 2026Oct 9, 2026Senior
Associate Director, Clinical Data ManagementUSA - New Jersey - WarrenSep 23, 2026Oct 9, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Last 2 years.

Clinical trials (lead sponsor) Showing 50 of 65

RecordTitlePhaseStatusStartPrimary completion
NCT01247207Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)Phase 3TerminatedNov 22, 2010Feb 10, 2026 (actual)
NCT05166161A Long-Term Safety Study of PTC923 in Participants With PhenylketonuriaPhase 3CompletedFeb 14, 2022Jul 21, 2026 (actual)
NCT06302348A Study of Sepiapterin in Participants With Phenylketonuria (PKU)Phase 3RecruitingMar 4, 2024Feb 28, 2031 (estimated)
NCT07779616Study of PTC844 in Participants With Active Rheumatoid ArthritisPhase 2Not yet recruitingAug 31, 2026Sep 30, 2027 (estimated)
NCT07681713Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)Phase 3Not yet recruitingAug 15, 2026Mar 15, 2029 (estimated)
NCT04903288A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric ParticipantsPhase 2Active, not recruitingMay 12, 2021May 22, 2023 (actual)
NCT04577352A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaPhase 2/Phase 3CompletedDec 17, 2020Apr 4, 2023 (actual)
NCT04378075A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyPhase 2/Phase 3TerminatedSep 28, 2020Mar 18, 2023 (actual)
NCT03179631Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyPhase 3CompletedJul 6, 2017Mar 5, 2022 (actual)
NCT02369731Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)Not listedCompletedApr 30, 2015Mar 31, 2025 (actual)
NCT05218655A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial DiseasePhase 3CompletedJun 22, 2022Apr 15, 2025 (actual)
NCT05515536A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich AtaxiaPhase 3Active, not recruitingDec 8, 2022Dec 31, 2027 (estimated)
NCT05485987A Study of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaPhase 2CompletedOct 12, 2022Aug 29, 2024 (actual)
NCT05349721Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALSPhase 2TerminatedMay 15, 2022Sep 26, 2024 (actual)
NCT05269355A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)Phase 2/Phase 3TerminatedMay 23, 2022Jun 17, 2024 (actual)
NCT02352896Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh SyndromePhase 2CompletedJan 31, 2014Oct 30, 2023 (actual)
NCT04336826A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)Phase 2CompletedDec 29, 2021Aug 7, 2023 (actual)
NCT03761095A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)Phase 1CompletedMar 13, 2019Feb 5, 2024 (actual)
NCT01370447EPI-743 for Mitochondrial Respiratory Chain DiseasesNot listedNo longer availableNot listedNot listed
NCT05099640A Study of PTC923 in Participants With PhenylketonuriaPhase 3CompletedSep 30, 2021Apr 3, 2023 (actual)
NCT03519711A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With HyperphenylalaninemiaPhase 1/Phase 2CompletedJan 3, 2019Oct 2, 2020 (actual)
NCT04439071A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)Phase 2/Phase 3TerminatedJul 9, 2020Jul 20, 2022 (actual)
NCT03783923A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)Phase 3TerminatedOct 31, 2019Jan 1, 2021 (actual)
NCT02647359Study of Ataluren in Participants With Nonsense Mutation AniridiaPhase 2CompletedJan 31, 2016Jan 22, 2021 (actual)
NCT03796637A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With AtalurenPhase 2CompletedApr 11, 2019Jun 3, 2019 (actual)
NCT03648827A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)Phase 2CompletedDec 21, 2018Oct 23, 2020 (actual)
NCT03761069Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute LeukemiasPhase 1TerminatedOct 29, 2018Dec 28, 2021 (actual)
NCT03712124A Study of CNSA-001 in Women With Diabetic GastroparesisPhase 2CompletedFeb 27, 2019Sep 8, 2019 (actual)
NCT01557400Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and CanadaPhase 3CompletedMay 20, 2012Jan 19, 2018 (actual)
NCT00759876Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)2TerminatedAug 13, 2008May 17, 2010 (actual)
NCT01140451Extension Study of Ataluren (PTC124) in Cystic FibrosisPhase 3CompletedAug 12, 2010Dec 2, 2013 (actual)
NCT02460679Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)Phase 2CompletedJan 14, 2016Feb 23, 2018 (actual)
NCT01721733Safety and Efficacy Study of EPI-743 in Children With Leigh SyndromePhase 2CompletedOct 31, 2012Feb 28, 2015 (actual)
NCT01728064Safety and Efficacy of EPI-743 in Patients With Friedreich's AtaxiaPhase 2CompletedDec 31, 2012Oct 31, 2015 (actual)
NCT02819557Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular DystrophyPhase 2CompletedJun 9, 2016Feb 9, 2018 (actual)
NCT02090959An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation DystrophinopathyPhase 3TerminatedMar 20, 2014Jun 12, 2018 (actual)
NCT01826487Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)3CompletedMar 26, 2013Aug 20, 2015 (actual)
NCT01009294Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)Phase 2TerminatedJan 13, 2010Mar 23, 2010 (actual)
NCT00847379Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)2BTerminatedJan 31, 2009May 24, 2010 (actual)
NCT01141075Ataluren for Nonsense Mutation Methylmalonic AcidemiaPhase 2TerminatedJul 19, 2010Nov 3, 2011 (actual)
NCT00947193Study of Ataluren (PTC124) in Hemophilia A and BPhase 2TerminatedOct 14, 2009Aug 30, 2011 (actual)
NCT00237380Safety and Efficacy of Ataluren (PTC124) for Cystic FibrosisPhase 2CompletedNov 30, 2005May 31, 2006 (actual)
NCT00803205Study of Ataluren (PTC124™) in Cystic FibrosisPhase 3CompletedSep 8, 2009Nov 12, 2011 (actual)
NCT02139306Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)Phase 3Completed2014-082016-11 (actual)
NCT02456103Extension Study of Ataluren in Participants With Nonsense Mutation Cystic FibrosisPhase 3TerminatedAug 31, 2015Jun 2, 2017 (actual)
NCT00592553Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)2BCompletedFeb 29, 2008Dec 31, 2009 (actual)
NCT02107859Study of Ataluren (PTC124) in Cystic FibrosisPhase 3TerminatedMay 23, 2014Jun 5, 2017 (actual)
NCT00458341A Study of Ataluren in Pediatric Participants With Cystic FibrosisPhase 2CompletedMar 23, 2007Feb 29, 2008 (actual)
NCT04117880A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia2WithdrawnDec 31, 2018Jan 31, 2021 (estimated)
NCT03642145A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)Phase 3WithdrawnOct 31, 2018Jul 31, 2021 (estimated)

FDA records (last 2 years)

Connect

See your connections at PTC Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback